Added prognostic value of DCE blood volume imaging in patients with suspected recurrent or residual glioblastoma-A hybrid [ 18 F]FET PET/MRI study.

Autor:	Henriksen OM; Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark., Muhic A; Department of Oncology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark., Lundemann MJ; Department of Oncology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.; Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark., Larsson HBW; Department of Clinical Medicine, Faculty of Health and Medical Science, University of Copenhagen, Copenhagen, Denmark.; Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark., Lindberg U; Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark., Andersen TL; Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark., Hasselbalch B; Department of Oncology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark., Møller S; Department of Oncology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark., Marner L; Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital Bispebjerg, Copenhagen, Denmark.; Department of Clinical Medicine, Faculty of Health and Medical Science, University of Copenhagen, Copenhagen, Denmark.; Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark., Madsen K; Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark., Larsen VA; Department of Radiology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark., Poulsen HS; The DCCC Brain Tumor Center, Danish Comprehensive Cancer Center, Copenhagen, Denmark., Hansen AE; Department of Radiology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.; Department of Clinical Medicine, Faculty of Health and Medical Science, University of Copenhagen, Copenhagen, Denmark.; Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark., Law I; Department of Clinical Medicine, Faculty of Health and Medical Science, University of Copenhagen, Copenhagen, Denmark.; Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
Jazyk:	angličtina
Zdroj:	Neuro-oncology advances [Neurooncol Adv] 2024 Nov 18; Vol. 6 (1), pp. vdae196. Date of Electronic Publication: 2024 Nov 18 (Print Publication: 2024).
DOI:	10.1093/noajnl/vdae196
Abstrakt:	Background: Magnetic resonance imaging (MRI) cerebral blood volume (CBV) measurements improve the diagnosis of recurrent gliomas. The study investigated the prognostic value of dynamic contrast-enhanced (DCE) CBV imaging in treated IDH wildtype glioblastoma when added to MRI or amino acid positron emission tomography (PET). Methods: Hybrid [ 18 F]FET PET/MRI with 2CXM (2-compartment exchange model) DCE from 86 adult patients with suspected recurrent or residual glioblastoma were retrospectively analyzed. High CBV tumor volume (VOL CBV ), and contrast-enhancing (VOL CE ) and [ 18 F]FET active tumor (VOL FET ) volumes were delineated. Absolute and fractional high CBV subvolumes within VOL CE and VOL FET were determined. Associations with overall survival (OS) were assessed by Cox analysis. Results: Adjusted for methyltransferase gene status and steroid use all total tumor volumes were individually associated with shorter OS. Adding VOL CBV to VOL CE or VOL FET only the effect of VOL CBV was prognostic of OS (hazard ratio [HR] 1.327, P  = .042 and 1.352, P  = .011, respectively). High CBV subvolumes within both VOL CE and VOL FET were associated with shorter survival (HR 1.448, P  = .042 and 1.416, P  = .011, respectively), and the low CBV subvolumes with longer survival (HR 0.504, P  = .002 and .365, P  = .001, respectively). The fraction of VOL CE and VOL FET with high CBV was a strong predictor of OS with shorter median OS in upper versus lower tertiles (8.3 vs 14.5 months and 7.1 vs 15.6 months, respectively, both P  < .001). Conclusions: The high CBV tumor volume was a strong prognosticator of survival and allowed for the separation of high- and low-risk subvolumes underlining the heterogeneous physiological environment represented in the contrast-enhancing or metabolically active tumor volumes of treated glioblastoma. Competing Interests: The authors declare no competing interests. (© The Author(s) 2024. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu